{"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}],"groups":[{"description":"INCB001158 dosed at 50mg BID in combination with epacadostat (100 mg BID) and pembrolizumab (200 mg Q3W)","id":"BG000","title":"INCB001158 50mg BID+ Epacadostat + Pembrolizumab"},{"description":"INCB001158 dosed at 75mg BID in combination with epacadostat (100 mg BID)and pembrolizumab (200 mg Q3W)","id":"BG001","title":"INCB001158 75 mg BID + Epacadostat + Pembrolizumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"title":"Age, Continuous"},{"classes":[{"categories":[{"title":"Female"},{"title":"Male"}]}],"title":"Sex: Female, Male","unitOfMeasure":"participants"},{"title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}],"populationDescription":"No patients were analyzed due to insufficient numbers and risk of identifying patient by reporting data on 1 person enrolled in cohort 2"}